RESI JPM 2027 on Track to Surpass Last Year’s 850 Investors and Licensing Partners

October 20, 2026October 20, 2026 ~ Next Phase Admin ~ Leave a comment

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

More than 100 investors and licensing partners have already confirmed for RESI JPM 2027, and we are on pace to pass the 850 who attended last year

That number deserves a second look. Most conferences report total attendance, which is mostly other companies. 850 is the buy side alone: venture capital, corporate venture, family offices, angel groups, strategic investors, and pharma business development teams. People with mandates and checkbooks, in one room, during the one week of the year when the entire industry is already in San Francisco.

Meet the Confirmed Investors

RESI JPM runs in person on January 11 and 12 at the San Francisco Marriott Marquis, with three additional days of virtual partnering on January 13, 18, and 19. It is LSN’s largest conference of the year.

Why Density Is the Product

The hard part of early-stage fundraising is not the pitch. It is access.

Institutional calendars during JPM Week are locked months in advance, and an early-stage company without an existing relationship generally cannot get on them. The companies that do well that week are the ones who were already in the conversation.

RESI was built to change the math. Instead of chasing a handful of meetings around the city, you walk into a room with hundreds of active investors and licensing partners and you select who you want to meet before you arrive.

What Is Coming to RESI JPM 2027

The confirmed group spans the full early-stage ecosystem: venture capital, corporate venture arms, family offices, angel groups, strategic investors, and pharma and medtech business development. Mandates cover therapeutics, diagnostics, medical technology, digital health, and platform technologies, across preclinical through Phase 2.

How to Get the Most Out of It

Partnering meetings. Our system lets you filter the investor audience by stage, indication, geography, and check size, then request meetings directly. You build your own schedule rather than hoping for a hallway encounter.
The Innovator’s Pitch Challenge. Present to a live investor panel, get scored feedback in front of the room, and put your company in front of people who are evaluating in real time. Applications close on Wednesday, November 11.
Three virtual partnering days. January 13, 18, and 19 extend your reach to investors who could not travel, including a large international contingent who partner with us remotely.

Register

Registration is open now, and the investor count is still climbing. The earlier you register, the earlier you can start requesting meetings against the confirmed list.

Watch the Asset Flow, Not the Equity Flow: What I Learned at BioJapan

October 20, 2026October 20, 2026 ~ Next Phase Admin ~ Leave a comment

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

I recently returned from BioJapan, and the one takeaway I want to share with my global network is this: stop viewing Asia Pacific as a single market.

Regulations on both sides of the Pacific have made equity deals between the US and China much harder. But capital hasn’t stopped moving. It has changed form. Where equity deals run into friction, pharma licenses the asset instead. Chinese biotechs out-licensed $60 billion of assets in the first quarter of this year alone, up 73% from the same period a year earlier. That includes AstraZeneca’s deal with CSPC worth up to $18.5 billion. Large pharma faces a steep patent cliff before 2030, so its appetite for clinical-stage assets isn’t going away.

So watch the asset flow, not the equity flow. Here is what actually changed for me in Japan. I went in thinking about APAC as one market with local variations. It isn’t. It is three markets with three completely different jobs, and once you see them separately, the whole region stops looking confusing.

Three Markets, Not One

Each market plays a different role. China produces more assets than its domestic capital can absorb. Australia and Southeast Asia have the clinical infrastructure others can use. Japan and Korea stand out because they have both: a growing supply of academic innovation and deep corporate balance sheets looking for it.

Region

Sell Side
(Early-Stage Assets)

Buy Side
(VC / PE / Pharma)

Characterization

Mainland China

A large volume of high-quality assets, many moving faster than domestic capital can fund them

Domestic equity is selective and US venture investment has pulled back, while global pharma licensing runs at record levels

“The Asset Reservoir”

Japan, South Korea, & Taiwan

A deep, largely untapped pool of academic assets, alongside mature platforms: ADCs and regenerative medicine in Japan, AI-driven discovery and diagnostics in Korea. Taiwan continues to produce world-class assets

Active corporate venture arms and well-capitalized conglomerates

“The Strategic Capital Track”

Australia & Southeast Asia

Excellent trial infrastructure producing fast, high-quality human data

Cross-border investors using local efficiency as a launchpad for global programs

“The Clinical Fast Track”

Japan: Where Assets Meet Capital

Universities such as the University of Tokyo, Kyoto University, Keio University, Osaka University, Kobe University, and the University of Tsukuba, with RIKEN anchoring the discovery end, are producing a remarkable range of new assets across drugs, devices, diagnostics, and digital health. What’s new is a coordinated government effort to carry those assets to market:

AMED runs a 2:1 double match-up program. When a registered VC invests in a Japanese drug discovery startup, AMED can add up to twice that amount in non-dilutive funding, awarded per pipeline rather than per company, so a startup with three approved programs can draw on it three times.
MEDISO, under the Ministry of Health, Labor and Welfare, pairs ventures and university spinouts with experts in regulatory affairs, international development, and fundraising.
J-Bridge, run by JETRO, connects international innovators with Japanese corporates.

Three state-backed institutions, answering to different ministries, are working on the same bottleneck, and regional clusters are carrying that work into the field. For global investors and partners, that means Japanese assets now arrive better funded and better prepared, and Japanese corporate capital is easier to reach than it has been in years.

One Japanese advantage almost nobody prices correctly: Japan maintains a conditional, time-limited approval pathway for regenerative medicine products that can grant market access on evidence of probable benefit. No other major market offers that. If you have a cell or gene therapy and have never looked at Japan as a first market rather than a third one, you are leaving an option unexercised.

KBIC, the Kobe Biomedical Innovation Cluster, and LSN are working together to strengthen the commercialization pathway for Japanese life science companies through entrepreneur education, company preparation, capital formation, and international business development. At BioJapan in October, LSN presented joint sessions with KBIC, including one alongside MEDISO, on startup readiness and global fundraising.

RESI Asia: Tokyo and Kobe

That is why RESI is coming to Japan. RESI Asia Japan convenes in Tokyo on April 13, 2027, for global partnering. We expect to announce more events around RESI before and after the 13^th

The Bottom Line

Regulatory boundaries have changed the rules, but pharma’s appetite for licensing shows the underlying science has never been more valuable. Watch the asset flow, not the equity flow. I look forward to seeing many of you in Tokyo next April.

RESI Asia Japan Registration:

Japan-base Registration (JPY)

Non-Japan-base Registration (USD)

The Missing Piece in Preparing Life Science Companies for Investors

October 14, 2026October 14, 2026 ~ Next Phase Admin ~ Leave a comment

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

One of the most pervasive problems we see across life science entrepreneurial programs is that Entrepreneurs-in-Residence (EIRs) help companies develop executive summaries and pitch decks that emphasize the science and market opportunity. This approach repeats across incubators, accelerators, universities, and entrepreneurial training programs worldwide.

The problem is that the two sides of the table are speaking different languages. The sell side presents science and market potential, while investors and licensing partners evaluate the seven-layer risk stack: market, technical, regulatory, execution, economic, financing, and exit risk. They want to understand which risks have been retired, which remain, and what evidence supports the company’s ability to overcome them.

This is precisely where LSN spends its time preparing companies for global roadshows and RESI partnering events.

We begin with the LSN assessment, which identifies where the company sits within the risk stack, what has been accomplished, and what remains to be de-risked. We then reconstitute the executive summary and pitch deck to speak the language of risk, supported by evidence rather than simply promoting the science and market opportunity.

We also develop a milestone-driven Gantt chart that shows the development milestones already completed and the value created, the one, two, or three critical milestones ahead for the remainder of the current year, and the subsequent development and de-risking milestones planned for years two and three.

The capital ask becomes the financial expression of the de-risking plan. By calculating the cost of the current and future milestones, the company can explain precisely how much capital it needs, what that capital will accomplish, which risks will be retired, and how achieving those milestones is expected to increase the asset’s value.

This is the fundamental distinction between a conventional pitch deck and a de-risked deck. One emphasizes the promise of the science and the size of the market. The other demonstrates a credible, milestone-driven, financed pathway to making that science investable.

That is the missing commercialization discipline LSN brings to the table, and it is what investors and licensing partners are looking for.

RESI JPM 2027 Investor Panel Lineup Announced

October 14, 2026October 14, 2026 ~ Next Phase Admin ~ Leave a comment

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation is pleased to announce the finalized investor panel lineup for RESI JPM 2027, taking place January 11 and 12 at the San Francisco Marriott Marquis during J.P. Morgan Healthcare Week.

The two day program features 14 investor sessions across therapeutics, medtech, diagnostics, digital health, platform technologies, strategic partnerships, and alternative sources of capital.

Monday, January 11

9:00 AM | Follow the Money [2027 Outlook & Trends]

Where Life Science & Healthcare Investors See Opportunity in 2027

Every year at JPM, one question sets the tone for the week: where is the capital going? Investors from across therapeutics, medtech, diagnostics, digital health, and tools take the stage to share what they are seeing in fundraising, valuations, and exit windows. They will discuss which sectors are attracting conviction, which are being left behind, and how their own priorities have shifted since last year. Whether you are raising, investing, or building, this is the read on the market you need before the deals begin.

10:00 AM | What Is Fundable Now: Therapeutics [Early Stage Therapeutics]

What Earns a Term Sheet from Early Stage Biotech Investors

Early stage therapeutics investors must weigh scientific promise against the risks of translating it into a viable treatment. Seed through Series A investors get candid about what earns their conviction: differentiated biology, convincing translational evidence, and a credible clinical development strategy. The discussion explores how investors assess target validation, competitive positioning, safety, and the experiments needed to reduce key development risks. Expect frank talk about what makes them lean in, what makes them pass, and how founders can make a compelling scientific and investment case for a therapeutic program.

11:00 AM | Backing the Next Medical Breakthrough [Medical Devices]

How Investors Evaluate Early Stage Device Innovation

Medical device companies face distinct investment hurdles, from proving technical feasibility to establishing a path to clinical adoption. This panel brings together medtech investors to discuss how they evaluate early stage opportunities across surgical technologies, robotics, monitoring, wearables, and home care. The conversation examines clinical need, regulatory strategy, reimbursement, usability, and the evidence required to support adoption. Hear what makes a device differentiated, how investors assess development and commercial risk, and which milestones strengthen the case for investment.

1:00 PM | Strategics at the Table [Strategics]

How Corporate Partners Decide When to Invest, Partner & Acquire

Strategic partners are shaping which technologies reach patients, and they are increasingly involved long before a company is ready to sell. Business development leaders from pharma and medtech join corporate venture investors to explain when they engage, what they need to see, and how they think about partnering, investing, and acquiring. Learn how to get on a strategic partner’s radar, what makes a startup stand out in a crowded pipeline, and how to build a relationship that lasts beyond a single deal.

2:00 PM | The First Believers [First Check Investors]

How the Earliest Backers Turn Life Science Ideas into Fundable Companies

Every great company has someone who said yes first. This panel gathers the earliest backers in life sciences: angels, seed funds, venture studios, foundations, and accelerators. They explain how they evaluate opportunities before substantial scientific or commercial validation, what they look for in a founding team, and what gives them the conviction to write the first check. The conversation covers company formation, initial experiments, and how early capital and hands on support help founders establish a credible development path. For founders at the very start, it is a candid map of the road from initial concept to the first funded development milestones.

3:00 PM | The Brain Trust [CNS / Neuro]

Investing Across Neuroscience & Psychiatry

Few areas of medicine combine such enormous unmet need with such complex investment challenges. This panel brings together investors in therapeutics, neuromodulation devices, digital biomarkers, and diagnostics to discuss what draws capital into neuroscience and psychiatry. Together they explore how advances in biology, technology, and clinical trial design can reopen areas once considered too difficult, and how founders across modalities can position themselves to attract investment.

4:00 PM | Patient Capital [Family Offices]

How Family Offices Are Investing Directly in Life Sciences

Family offices offer a distinct route to life science capital through direct investing, syndication with peers, and investment structures that can support longer time horizons. This session explores what draws private capital to highly technical opportunities, how family offices diligence science and technology, and what founders should know before approaching them. Panelists discuss how they structure investments, work with specialist co-investors, and assess follow-on needs. It is a practical look at how to earn the confidence of this diverse investor community.

Tuesday, January 12

9:00 AM | Investing in Longer, Healthier Lives [Longevity]

The Science and Technologies Addressing Age Related Disease

Helping people live longer, healthier lives requires addressing the diseases and functional challenges that come with aging. This panel brings together therapeutics, medtech, diagnostics, and digital health investors to explore opportunities in cardiometabolic disease, musculoskeletal health, physical function, and maintaining independence. The discussion examines how investors evaluate treatments for specific age related conditions alongside technologies that address underlying aging biology, detect risk earlier, or help people remain active. Hear what constitutes meaningful clinical evidence, how companies define a viable path to market, and what makes an opportunity compelling for early stage investment.

10:00 AM | Digital Health After the Hype [Digital Health]

What Investors Want to See in Evidence, Adoption & Economics

The digital health market has been through a reset. Investors discuss what they are backing now: clinical grade AI, new models of care delivery, and businesses with evidence, engagement, and economics that hold up to scrutiny. Hear where value is being created, what has changed in how these companies are evaluated, and what separates durable businesses from those that struggle to convert adoption into sustainable growth.

11:00 AM | Enabling the Next Generation of Medicine [Platform Technologies]

Investing in Discovery Platforms, Delivery Technologies & Research Tools

Some of the most valuable companies in life sciences make new medicines possible. This panel brings together investors backing AI enabled discovery platforms, delivery technologies, synthetic biology, and the research tools that accelerate development. The conversation centers on how to separate a durable platform from a clever technology, how investors evaluate platform companies alongside tools and infrastructure businesses, and how business models differ from those of asset driven companies. Hear what makes these technologies investable and where founders can build lasting value.

1:00 PM | Capital Across Borders [Cross Border Investors]

How International Investors Evaluate and Finance Life Science Companies

Cross border investment can expand a company’s funding options, but attracting international capital requires understanding how investors evaluate opportunities beyond their home markets. This panel brings together investors from different regions to discuss geographic mandates, due diligence, syndication, and the local presence or development plans they expect from companies abroad. Hear what makes a company attractive to overseas investors, how investors work with local co-investors, and how founders can build relationships that lead to cross border financing.

2:00 PM | Runway Without the Round [Beyond Venture Capital]

Financing the Next Milestone Beyond Conventional Venture Equity

A conventional venture round is not the only way to fund a company. This panel explores non dilutive grants, foundation funding, venture debt, royalty financing, strategic agreements, and government backed programs. Capital providers explain who qualifies, what stage or evidence their funding requires, how long the process takes, and what obligations or tradeoffs founders should understand. The discussion examines which sources are suitable for early stage companies and how they can complement equity financing. Hear how to match funding to a development milestone and extend runway without relying solely on another conventional venture round.

3:00 PM | From Seed to Series A

Building the Evidence and Investor Confidence for the Next Round

Securing seed funding is only the beginning. This panel brings together seed investors and Series A investors to explore how life science companies turn initial funding into a financeable next round. The discussion covers setting achievable milestones, demonstrating progress against the original investment thesis, identifying a lead investor, and building a syndicate. Across therapeutics, medtech, and digital health, panelists discuss how founders should align development plans, capital needs, and fundraising timelines. Hear how existing investors assess follow-on support, what new investors need to see, and how to address gaps that can leave promising companies between rounds.

4:00 PM | The Investor Reverse Pitch

Meet the Investors and Discover What They Want to Fund

To close the conference, the roles flip. Investors from across therapeutics, medtech, diagnostics, digital health, and tools take the stage to pitch their mandates: what they invest in, at which stage, with what check size, and what gets their attention. Investors deliver short presentations, followed by audience Q&A. Founders leave with a clear list of who to follow up with and how to approach them. It is a practical, high energy finish to two days of conversations.

Speaker Submissions

Life Science Nation is currently seeking qualified investors, corporate business development leaders, family office representatives, and other capital providers for speaker consideration. Submit a speaker application.

Submit a speaker application

Fundraising Requires More Than a Plan. It Requires Execution. (Part 2)

October 14, 2026October 14, 2026 ~ Next Phase Admin ~ Leave a comment

By Max Braht, VP of Business Development, LSN

Experienced life science executives who have successfully raised capital understand something that first-time fundraisers often underestimate: a successful fundraising campaign is not built around a handful of investor introductions or a series of meetings at industry conferences. It is built around a large, qualified, continuously evolving list of investor and licensing-partner targets, supported by the disciplined execution required to keep that list working throughout the campaign.

Last week, I discussed why fundraising requires both a focused strategy and consistent execution. But there is another critical component that deserves more attention: the target list itself. It is the foundation of the entire campaign, and building, maintaining, and continually replenishing that list is one of the most demanding aspects of raising capital.

At Life Science Nation, we have found that experienced fundraising executives are often the first to recognize the value of our BD Assist program. They have been through the process before. They understand that a serious life science fundraising campaign can take 9–18 months, and that a campaign of that duration needs to begin with approximately 800–1,000 qualified investor and licensing-partner targets.

Just as importantly, they know that the original list will not remain intact. Investors respond, decline, change their investment mandates, move into diligence, or prove to be inappropriate targets. Some relationships advance while others are eliminated from consideration. Throughout this process, new qualified targets must continually enter the pipeline to replace those that have fallen away. The campaign is constantly moving, with prospects entering, advancing, and exiting at different stages.

The target list is not a static spreadsheet. It is the engine that drives the fundraising campaign.

Keeping that engine running requires much more than sending emails. It means identifying investors whose investment theses align with the company’s technology, development stage, financing requirements, and geography. It means researching investment activity, finding the appropriate contacts, developing compelling messaging, canvassing prospects, tracking responses, managing follow-up, and maintaining a steady flow of new opportunities.

Experienced executives know how difficult this is because they have done it themselves. They understand that maintaining a professional fundraising campaign often requires a dedicated full-time resource whose responsibility is to keep the target list accurate, active, and continuously replenished. They also know how tedious and time-consuming that work can become, particularly while managing the scientific, clinical, regulatory, financial, and operational responsibilities of an emerging life science company.

This is the fundamental value proposition of LSN’s BD Assist program. LSN has spent years building and maintaining a global database of investors and licensing partners, developing the market intelligence and processes required to identify appropriate targets and execute sustained fundraising campaigns. BD Assist combines that infrastructure with the daily canvassing, outreach, scheduling, tracking, and follow-up needed to keep a campaign moving forward. Rather than building this capability internally, executives can leverage LSN’s existing database, investor intelligence, and business development team to maintain the campaign engine while they concentrate on running their companies and advancing relationships with interested investors.

The value is not simply that BD Assist takes work off an executive’s desk. It provides access to an established fundraising infrastructure that would otherwise take considerable time, money, and effort to replicate.

Timing: Preparing for RESI JPM

The life sciences industry is now preparing for JPM Healthcare Week, when biotech, medtech, diagnostics, digital health, and investment professionals from around the world will gather to establish new relationships and advance existing ones. RESI JPM provides an important opportunity for early-stage companies to meet investors and licensing partners whose interests align with their development and financing objectives. But experienced fundraisers know that conferences are not standalone fundraising strategies. They are opportunities within a much larger campaign.

The companies that benefit most from RESI are those that arrive with a well-developed target list, know which investors they need to meet, have already begun their outreach, and are prepared to continue those conversations long after the conference concludes.

A meeting at RESI may initiate a relationship, advance an existing discussion, or reveal that an investor is not an appropriate fit. Each outcome provides information that helps refine the target list and determine the next step. Meanwhile, the broader fundraising campaign must continue generating new prospects, new conversations, and new opportunities.

RESI creates access. The continuously replenished target list and the execution behind it turn that access into a sustained fundraising campaign.

For executives who have raised capital before, none of this is new. They know what it takes to build a successful campaign, and they know how difficult it is to keep the engine running for 9–18 months. What LSN offers through BD Assist is the infrastructure, investor intelligence, and dedicated execution capability to help them do exactly that.

Ready to Put Your Fundraising Campaign into Motion?

If you are preparing for RESI JPM or planning a sustained fundraising campaign, LSN’s BD Assist team can help you build, maintain, and continuously canvass the global investor and licensing-partner target list that drives the process.

Because a successful fundraising campaign does not run on meetings alone. It runs on a continuously replenished pipeline of qualified targets.

Get Your LSN Labs Company Assessment Report

Prepare for RESI JPM 2027: Join Life Science Nation’s Upcoming Webinars

October 14, 2026 ~ Next Phase Admin ~ Leave a comment

By Karen Deyo, VP of Product, Israel BD, LSN

As RESI JPM 2027 approaches, Life Science Nation is hosting three complimentary webinars to help life science innovators strengthen their fundraising strategy, make the most of partnering opportunities, and better understand the investor landscape.

RESI JPM takes place January 11–12, 2027, in person at the San Francisco Marriott Marquis during J.P. Morgan Healthcare Week, followed by virtual partnering on January 13, 18, and 19. Whether you are preparing to attend RESI JPM or developing your broader fundraising strategy, these sessions offer practical guidance to help you make meaningful connections with the right partners.

Life Science Nation Event Partnering Process

Monday, November 2, 2026 | 11:00 AM–12:00 PM ET

Attending partnering events plays a key role in the success of any fundraising campaign. Join this free webinar to learn Life Science Nation’s proven strategy for effective event partnering.

The session will cover how to craft compelling outreach messages and follow-ups that drive engagement and build lasting connections with potential partners. Save your spot and elevate your fundraising efforts with insights you will not want to miss.

RESI JPM Partnering Tutorial

Monday, November 16, 2026 | 11:00 AM–12:00 PM ET

Understanding the RESI partnering system and using it to its maximum capabilities can make a large difference in a company’s success at RESI. Join LSN staff for a walkthrough of the system and how it can help companies identify partners who are a best fit, manage outreach, follow up effectively, and take advantage of the content available to ensure the best possible RESI experience.

Global Investor Landscape

Thursday, December 17, 2026 | 11:00 AM–12:00 PM ET

Join Life Science Nation for an overview of the global investor landscape and the diverse sources of capital available to life science companies.

This webinar will explore what makes each investor type unique, from angels and venture capital firms to family offices, corporate investors, and other strategic sources of funding. Learn what each group typically looks for, how their investment approaches differ, and what innovators should consider when evaluating potential investor fit.

Fundraising Requires More Than a Plan. It Requires Execution.

October 6, 2026October 6, 2026 ~ Next Phase Admin ~ Leave a comment

By Max Braht, VP of Business Development, LSN

For early-stage life science companies, fundraising and partnering are not one-time activities. They require an ongoing, focused effort to identify the right market, communicate a clear opportunity, build relationships, and follow through consistently.

Many companies have the science, the data, and the ambition to move forward, but do not have a dedicated business development resource to manage that work throughout the year. Leadership teams are often balancing scientific progress, regulatory planning, operations, and fundraising at the same time.

Life Science Nation’s BD Assist program was developed to provide hands-on support for companies that need help executing their fundraising and partnering campaigns.

BD Assist is the execution layer of Life Science Nation’s commercialization system. It builds on the work of understanding a company’s readiness, identifying the right investor and licensing-partner market, and creating a Global Target List that can support a focused campaign.

The result is not simply a list of contacts. It is a structured process for moving from market intelligence to outreach, follow-up, and meeting generation.

From target market to active campaign

Every BD Assist engagement begins with an understanding of the company’s goals, financing needs, technology, milestones, and partnering objectives. Life Science Nation then works with the company to refine its narrative and marketing materials so the opportunity can be communicated clearly to the market.

Using Life Science Nation’s investor and licensing-partner intelligence, the BD Assist team helps construct and prioritize a Global Target List of relevant investors and strategic partners. The target list is informed by company-specific attributes as well as investor behavior, helping companies focus their efforts on the market most relevant to their opportunity.

From there, BD Assist supports campaign strategy, personalized outreach, follow-up, and meeting generation. Outreach activity is tracked through the client’s CRM platform, allowing the company to maintain visibility into campaign progress and investor engagement.

This ongoing execution is a key part of the program. A target list has value only when it becomes a disciplined campaign that continues to build relationships and create opportunities over time.

Extending a company’s business development capacity

BD Assist is designed to become an extension of a company’s business development capability.

Rather than providing recommendations for a company to carry out on its own, Life Science Nation helps manage the campaign workflow. This allows company leadership to stay focused on advancing the science, reaching development milestones, and preparing for productive investor and partner conversations.

The program also includes regular strategy discussions and campaign refinement as the company receives feedback from the market. As priorities evolve, BD Assist can help ensure that outreach remains aligned with the company’s current fundraising or partnering objectives.

For companies participating in RESI, BD Assist can also support their partnering activity and help them make the most of the investor and licensing-partner marketplace.

Part of a broader commercialization process

BD Assist is one part of a connected Life Science Nation commercialization system.

The Assessment Engine helps companies understand their evidence, risks, milestones, capital readiness, and investability. LSN Labs helps companies address gaps and prepare for the market. The Investor and Licensing Partner Database provides market intelligence. The Global Target List helps companies identify and prioritize their target market. BD Assist helps execute the campaign. RESI creates opportunities to meet the global investor and licensing-partner community.

For companies seeking investment, licensing opportunities, or strategic collaborations, this creates a more connected path from preparation to market engagement.

Fundraising is not only about finding names. It is about executing a consistent process that helps the right companies connect with the right market at the right time.

To learn more about BD Assist and discuss whether it is a fit for your company, complete the LSN Labs Company Assessment Report.

Apply for LSN Labs Company Assessment Report